Fifty 1 Labs and UAV Corp to Host Virtual Shareholder Teleconference Featuring Nobel Laureate Dr. James Orbinski
Fifty 1 Labs, Inc. (OTC: FITY), in collaboration with UAV Corp (OTC: UMAV), is set to host a virtual shareholder
ATLANTA, GA — April 16, 2026 — Red Hawk Vending, a Metro Atlanta-based provider of workplace refreshment solutions including vending, micro...
A deeper look at recent coverage suggests improving fundamentals, despite near-term margin pressure and headline-driven volatility Houston, TX, April 14th,...
DEL MAR, CA — April 10, 2026 – The Pharma Partnering Summit (PPS US) 2026 is set to return to...
Fifty 1 Labs, Inc. (OTC: FITY), in collaboration with UAV Corp (OTC: UMAV), is set to host a virtual shareholder
Want to earn more points, get a higher credit limit, or take advantage of exclusive travel perks? Upgrading your credit card can help unlock a range of additional benefits. Many credit card companies...
The American Heart Association has announced the expansion of its Cardiovascular-Kidney-Metabolic Health Initiative to
AIX (Artificial Intelligence Exchange), in collaboration with HR.com, has announced a significant strategic shift tow
Firefly Aerospace, a prominent player in the space and defense technology arena, has commenced the roadshow for its ini
Telvantis Voice Services Inc., a subsidiary of Telvantis Inc., and Adya Inc. have announced a strategic collabora
Phylax Global has announced the launch of military-style tactical training courses specifically designed for civilia
Residents and businesses in Dallas now have access to specialized legal support for resolving complex tax issues,
Compass Diversified Holdings (NYSE: CODI) has announced a significant extension of its forbearance agreement with its
BitFrontier Capital Holdings, Inc. (OTC: BFCH) has announced the complete retirement of all outstanding legacy convert
White Stallion Hay has announced its commitment to breeding and selling top-quality Andalusians specifically fo
Lexaria Bioscience Corp. has released promising interim results from its phase 1b study, GLP-1-H24-4, showcasing